Plan debates typically return to scheduling and bans. India and the United States both equally confront variations of precisely the same question: regardless of whether to impose broader, course-broad controls about fentanyl analogs and their precursors, or to help keep material-by-compound scheduling that may lag driving traffickers’ innovation.